|
Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD) Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD) Clinical research trials and Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD) healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD). Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD) Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD) clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD) condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD)  Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD)
Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD)
For Condition: Attention Deficit Disorder with Hyperactivity,Substance-Related Disorders,Dyssocial Behavior
Status: No longer recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive skills; peer relations) that may influence adolescent functioning (either independent of or through initial treatment assignment and/or 14-month treatment outcomes); and to compare how these predictors, mediators, and moderators are similar or dissimilar within the normal comparison group. Aim 3 is to track the patterns of risk and protective factors (including their mediation or moderation by initial treatment assignment and/or outcome) involved in early and subsequent stages of developing substance-related disorders and antisocial behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of treatment success on later academic performance, achievement, school conduct, tendency to drop out, and other adverse school outcomes. In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions: (1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or (4) Assessment-and-Referral condition. All but the latter were treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment. A child may be eligible for this study if he/she: Is 7 - 9 years old, and has Attention Deficit Hyperactivity Disorder (ADHD).
Details: This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive skills; peer relations) that may influence adolescent functioning (either independent of or through initial treatment assignment and/or 14-month treatment outcomes); and to compare how these predictors, mediators, and moderators are similar or dissimilar within the normal comparison group. Aim 3 is to track the patterns of risk and protective factors (including their mediation or moderation by initial treatment assignment and/or outcome) involved in early and subsequent stages of developing substance-related disorders and antisocial behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of treatment success on later academic performance, achievement, school conduct, tendency to drop out, and other adverse school outcomes. In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions: (1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or (4) Assessment-and-Referral condition. All but the latter were treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment.
Eligibility:
Study Type: Interventional, Treatment, Randomized
Minimum Age/Maximum Age: 7 Years/9 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: Patients must have: Rigorously diagnosed Attention Deficit Hyperactivity Disorder (ADHD).
Total Enrollment:
Location and Contact Information:
Overall Study Official:
HowardAbikoff, Principal Investigator,
Additional Information:
Study ID Numbers: MH50453; MH50447,MH50454,MH50461,MH50467,MH50440
Study Start Date: September 1998
Record last reviewed: September 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000388
Other Attention Deficit Disorder With Hyperactivity Studies:
1. Antisocial Behavior: Passing From Parent to Child to Grandchild
2. Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD)
Related Studies:
Other Attention Deficit Disorder with Hyperactivity Clinical Trials
Other Clinical Trials
Other Clinical Trials
Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (ADHD)
|
|
|
|
|
|
|
|
